Neurocrine Biosciences, Inc. (NASDAQ:NBIX) announced its quarterly earnings data on Tuesday. The company reported ($0.13) EPS for the quarter, topping the Zacks’ consensus estimate of ($0.49) by $0.36, Bloomberg Earnings reports. The business had revenue of $60.77 million during the quarter, compared to the consensus estimate of $29.38 million. During the same period in the prior year, the firm earned ($0.43) EPS.

In related news, insider Haig P. Bozigian sold 26,250 shares of the business’s stock in a transaction dated Wednesday, September 6th. The stock was sold at an average price of $60.00, for a total value of $1,575,000.00. Following the sale, the insider now directly owns 144,601 shares in the company, valued at approximately $8,676,060. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink. Also, insider Christopher Flint Obrien sold 6,925 shares of the business’s stock in a transaction dated Monday, October 2nd. The shares were sold at an average price of $61.04, for a total value of $422,702.00. Following the completion of the sale, the insider now owns 55,898 shares in the company, valued at $3,412,013.92. The disclosure for this sale can be found here. Insiders sold a total of 123,846 shares of company stock worth $7,004,150 over the last 90 days. 4.80% of the stock is currently owned by company insiders.

An institutional investor recently raised its position in Neurocrine Biosciences stock. The Manufacturers Life Insurance Company boosted its position in Neurocrine Biosciences, Inc. (NASDAQ:NBIX) by 7.8% during the second quarter, according to its most recent 13F filing with the SEC. The firm owned 2,665 shares of the company’s stock after acquiring an additional 193 shares during the period. The Manufacturers Life Insurance Company ‘s holdings in Neurocrine Biosciences were worth $123,000 as of its most recent SEC filing.

ILLEGAL ACTIVITY WARNING: “Neurocrine Biosciences, Inc. (NBIX) Posts Earnings Results, Beats Expectations By $0.36 EPS” was first posted by American Banking News and is owned by of American Banking News. If you are reading this news story on another domain, it was stolen and reposted in violation of US & international trademark & copyright law. The original version of this news story can be accessed at https://www.americanbankingnews.com/2017/11/01/neurocrine-biosciences-inc-nbix-posts-earnings-results-beats-expectations-by-0-36-eps.html.

A number of brokerages have recently commented on NBIX. BMO Capital Markets reissued an “outperform” rating and issued a $84.00 price objective on shares of Neurocrine Biosciences in a research report on Thursday, October 5th. Leerink Swann reaffirmed an “outperform” rating and set a $72.00 price target (up from $67.00) on shares of Neurocrine Biosciences in a research report on Tuesday, October 10th. Jefferies Group LLC reaffirmed a “buy” rating and set a $69.00 price target (up from $66.00) on shares of Neurocrine Biosciences in a research report on Tuesday, October 3rd. Piper Jaffray Companies reaffirmed a “buy” rating and set a $76.00 price target on shares of Neurocrine Biosciences in a research report on Wednesday, October 25th. Finally, Oppenheimer Holdings, Inc. reaffirmed a “buy” rating and set a $70.00 price target on shares of Neurocrine Biosciences in a research report on Thursday, September 7th. Two investment analysts have rated the stock with a hold rating and seventeen have assigned a buy rating to the stock. The stock currently has an average rating of “Buy” and an average price target of $69.31.

Neurocrine Biosciences Company Profile

Neurocrine Biosciences, Inc is engaged in discovering and developing pharmaceuticals, in diseases with unmet medical needs, through its research and development (R&D) platform, focused on neurological and endocrine based diseases and disorders. Its three lead late-stage clinical programs are elagolix, which is a gonadotropin-releasing hormone (GnRH) antagonist for endometriosis and uterine fibroids; INGREZZA (valbenazine), which is a vesicular monoamine transporter 2 (VMAT2) inhibitor, for the treatment of movement disorders, and opicapone, which is a selective catechol-O-methyltransferase inhibitor that is an adjunct therapy to preparations of levodopa/Dihydroxyphenylalanine (DOPA) decarboxylase inhibitors for adult patients with Parkinson’s disease.

Earnings History for Neurocrine Biosciences (NASDAQ:NBIX)

Receive News & Ratings for Neurocrine Biosciences Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Neurocrine Biosciences Inc. and related companies with MarketBeat.com's FREE daily email newsletter.